• Rucaparib (AG-014699): Potent PARP1 Inhibitor for DNA Dam...

  2026-01-11

  Rucaparib (AG-014699, PF-01367338) is a highly potent PARP1 inhibitor with a Ki of 1.4 nM, widely used in DNA damage response and cancer biology research. Its unique ability to radiosensitize PTEN-deficient and ETS gene fusion-positive cancer cells makes it an essential tool for studying synthetic lethality and regulated cell death.

• Benzyl Quinolone Carboxylic Acid: Precision M1 Receptor P...

  2026-01-10

  Benzyl Quinolone Carboxylic Acid (BQCA) sets a new benchmark as a selective positive allosteric modulator of the M1 muscarinic acetylcholine receptor, enabling robust cognitive function modulation and advanced Alzheimer’s disease research. This guide delivers actionable protocols, troubleshooting insights, and cutting-edge applications to empower neuroscience workflows with APExBIO’s trusted BQCA.

• DiscoveryProbe™ FDA-approved Drug Library: Transforming S...

  2026-01-09

  Explore the DiscoveryProbe FDA-approved Drug Library as a next-generation tool for high-throughput screening, signal pathway regulation, and enzyme inhibitor discovery. Uncover unique scientific insights and advanced applications in cancer and neurodegenerative disease research.

• Rucaparib (AG-014699): Next-Generation Strategies in PARP...

  2026-01-09

  Explore how Rucaparib (AG-014699, PF-01367338) redefines DNA damage response research as a potent PARP1 inhibitor and radiosensitizer for prostate cancer cells. This article delivers a distinct, systems-level perspective, integrating advanced mechanistic insights and translational applications.

• Acifran: Mechanistic Insights and Strategic Guidance for ...

  2026-01-08

  This thought-leadership article explores the advanced mechanistic role of Acifran, a selective HM74A/GPR109A and GPR109B agonist, in lipid metabolism regulation. By integrating structural breakthroughs, experimental validation, and translational perspectives, it provides strategic guidance for researchers aiming to leverage Acifran in metabolic disorder research. The discussion is uniquely positioned to bridge foundational science with real-world laboratory strategy, setting a new standard beyond conventional product pages.

• JC-1 Mitochondrial Membrane Potential Assay Kit: Scenario...

  2026-01-07

  Discover how the JC-1 Mitochondrial Membrane Potential Assay Kit (SKU K2002) addresses real-world laboratory challenges in mitochondrial function analysis, apoptosis detection, and drug screening workflows. This article presents evidence-based, scenario-driven guidance for biomedical researchers and technicians seeking reproducible, quantitative, and practical solutions for ΔΨm measurement.

• Rucaparib (AG-014699): Unraveling PARP Inhibition and Apo...

  2026-01-06

  Discover how Rucaparib, a potent PARP inhibitor, advances DNA damage response research by integrating new insights into apoptotic signaling and RNA Pol II-mediated cell death. Explore its unique radiosensitization mechanisms and applications in PTEN-deficient and ETS fusion-positive cancer models.

• 3-Aminobenzamide: Potent PARP Inhibitor for Translational...

  2026-01-05

  3-Aminobenzamide (PARP-IN-1) stands out as a potent PARP inhibitor, driving reproducible breakthroughs in oxidative stress, immunometabolism, and diabetic nephropathy models. This guide delivers actionable workflows, troubleshooting strategies, and advanced applications, empowering researchers to maximize every experimental run with APExBIO's gold-standard reagent.

• Acifran: Selective HM74A/GPR109A Agonist for Lipid Metabo...

  2026-01-04

  Acifran is a highly selective HM74A/GPR109A and GPR109B agonist, enabling precise modulation of lipid signaling pathways for metabolic disorder research. Structural studies confirm its binding and selectivity, providing robust tools for dissecting G-protein coupled receptor function. This article summarizes atomic benchmarks, optimal usage parameters, and common misconceptions for practitioners.

• JC-1 Mitochondrial Membrane Potential Assay Kit: Precisio...

  2026-01-03

  The JC-1 Mitochondrial Membrane Potential Assay Kit sets the standard for sensitive, ratiometric mitochondrial membrane potential detection in apoptosis and mitochondrial function analysis. Its robust workflow, built-in CCCP control, and high-throughput compatibility empower researchers to advance cancer and neurodegenerative disease studies with unmatched reliability.

• Benzyl Quinolone Carboxylic Acid: Decoding M1 Receptor Si...

  2026-01-02

  Explore the advanced mechanisms by which Benzyl Quinolone Carboxylic Acid (BQCA) acts as a positive allosteric modulator of the M1 muscarinic acetylcholine receptor. This in-depth analysis reveals new insights into signaling bias, translational neuroscience, and Alzheimer’s disease research.

• JC-1 Mitochondrial Membrane Potential Assay Kit: Precisio...

  2026-01-01

  The JC-1 Mitochondrial Membrane Potential Assay Kit stands out for ratiometric, high-throughput ΔΨm measurement, streamlining apoptosis and mitochondrial function analysis in cancer and neurodegenerative disease research. Its robust workflow controls and built-in CCCP positive control ensure reproducible results—even in challenging experimental scenarios. Discover how this kit accelerates translational studies and overcomes common pitfalls in mitochondrial membrane potential detection.

• Rucaparib (AG-014699, PF-01367338): Potent PARP1 Inhibito...

  2025-12-31

  Rucaparib (AG-014699, PF-01367338) is a highly potent PARP1 inhibitor used in DNA damage response and radiosensitization research. It is particularly effective in PTEN-deficient and ETS gene fusion-expressing cancer models, with robust mechanistic evidence supporting its utility. This article clarifies its biological rationale, benchmarks, and workflow integration for advanced cancer biology studies.

• Benzyl Quinolone Carboxylic Acid (BQCA): Selective M1 Mus...

  2025-12-30

  Benzyl Quinolone Carboxylic Acid (BQCA) is a highly selective positive allosteric modulator of the M1 muscarinic acetylcholine receptor, offering robust potentiation for cognitive and Alzheimer’s disease research. This article presents verifiable mechanisms, quantitative evidence, and integration parameters for effective experimental use.

• Scenario-Driven Solutions with DiscoveryProbe™ FDA-approv...

  2025-12-29

  This article delivers an evidence-based, scenario-driven exploration of real laboratory challenges in cell viability, proliferation, and cytotoxicity assays, demonstrating how the DiscoveryProbe™ FDA-approved Drug Library (SKU L1021) enhances experimental reliability, reproducibility, and translational impact. Drawing on recent literature and practical workflow insights, we guide biomedical researchers in leveraging this FDA-approved bioactive compound library for high-throughput screening, drug repositioning, and pharmacological target identification.

15611 records 1/1041 page Next 12345 下5页 Last page